Clinical trial
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With…
NCT00078572 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00078572 |
|---|---|
| Title | Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer |
| Official title | A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, lapatinib (GW572016) |
| Enrollment | 408 |
| Start date | Mar 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Feb 1, 2010 |
| First posted | Mar 3, 2004 |
| Last update posted | Dec 13, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: